7.4.5. specific aspects treatment carcinoma situ. 7.4.5.1. treatment strategy detection concurrent cis increases risk recurrence progression tat1 tumours . case treatment according criteria summarised sections 7.4.2, 7.4.3 7.9 mandatory. carcinoma situ cannot cured endoscopic procedure alone. histological diagnosis cis must followed treatment, either intravesical bcg instillations rc. tumour-specific survival rates immediate rc cis excellent, large proportion patients might over-treated . 7.4.5.2. cohort studies intravesical bcg chemotherapy retrospective evaluations patients cis, complete response rate 48% achieved intravesical chemotherapy 72âˆ’93% bcg [232-235,356]. 50% complete responders might eventually show recurrence risk invasion and/or extravesical recurrence . 7.4.5.3. prospective randomised trials intravesical bcg chemotherapy unfortunately, rcts patients cis only. meta-analysis clinical trials comparing intravesical bcg intravesical chemotherapy patients cis shown significantly increased response rate bcg reduction 59% odds treatment failure bcg . eortc-gucg meta-analysis tumour progression, subgroup 403 patients cis, bcg reduced risk progression 35% compared intravesical chemotherapy immunotherapy . combination bcg mmc superior bcg alone . summary, compared chemotherapy, bcg treatment cis increases complete response rate, overall percentage patients remain disease free, reduces risk tumour progression. 7.4.5.4. treatment cis prostatic urethra upper urinary tract patients cis high risk extravesical involvement uut prostatic urethra. solsona et al., found 63% 138 patients cis developed extravesical involvement initially follow-up . patients extravesical involvement worse survival bladder cis alone . prostate, cis might present epithelial lining prostatic urethra prostatic ducts . situations distinguished tumour invasion prostatic stroma (stage t4a bladder tumours) immediate radical cystoprostatectomy mandatory. patients cis epithelial lining prostatic urethra treated intravesical instillation bcg. transurethral resection prostate improve contact bcg prostatic urethra . however, potential spread cis considered; suprapubic trocar-placed catheter used. patients prostatic duct involvement promising results bcg, small series. data insufficient provide clear treatment recommendations radical surgery considered . 7.4.5.5. summary evidence - treatment carcinoma situ summary evidencelecarcinoma situ cannot cured endoscopic procedure alone.4compared intravesical chemotherapy, intravesical bcg maintenance instillations increase complete response rate, overall percentage patients remain disease free, reduce risk tumour progression.1b